news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

global cancer burden data released by the world health organization's international agency for research on cancer show that there will be nearly 20 million new cases of cancer and nearly 10 million deaths worldwide in 2022. in,4.82 million new cancer cases and 2.57 million cancer deaths occurred in china.obviously, china is already a veritable “cancer country”.

"centralized purchasing will reduce drug prices." this concept has now been deeply rooted in the hearts of the people, especially in cancer treatment, which was previously expensive. after the nationwide centralized drug purchasing, the prices of a large number of anti-cancer drugs have dropped, giving more patients hope for treatment and survival. hope.

“in the past, when it came to tumor drugs or anti-tumor treatments, everyone felt that they cost money and suffered.”a breast doctor from a well-known tertiary hospital in jiangsu province told the health information bureau that after the national centralized procurement work was launched, the prices of many common oncology drugs have dropped significantly, at least in terms of financial burden, which has greatly alleviated patients' worries.

take docetaxel as an example. this paclitaxel anti-tumor drug is a commonly used clinical chemotherapy drug and has good curative effect on advanced breast cancer, ovarian cancer, and non-small cell lung cancer. in june 2021, in the fifth batch of national drug procurement, the shortlisted anti-tumor drugs include 7 varieties including oxaliplatin injection and decitabine injection. indocetaxel injection dropped from 302.4 yuan per vial to 22.6 yuan per vial, a decrease of 92.52%.

in august this year,the jianshi bureau follows authoritative experts in the industry to investigate companies and hospitals.trying to understand whether centralized medicines are effective in cancer treatment, which is of widespread concern to the public?

the price of some selected products has been reduced by more than 90%

centralized purchasing reduces financial burden on cancer patients

“our patients don’t know which medicines are good and which medicines are not good, so we basically listen to the doctor.” during the survey, many patients told the jianshi bureau,as long as the disease can be cured, they are willing to accept the doctor's professional advice.

many experts said: the standard of clinical diagnosis and treatment is to always put the patient first. in other words, if the medicine is not easy to use and cannot cure the disease, no matter how cheap it is, doctors will not use it.

the use of anti-tumor drugs is closely related to the incidence of tumors. it is impossible to prescribe more chemotherapy drugs to patients just because centralized purchasing has reduced prices.according to data from multiple hospitals, the clinical dosage of docetaxel has been stable in the three years from 2021 to now.

the quantity has not fluctuated greatly, but the price has dropped a lot. taking "docetaxel injection" as an example, the original price was 302.4 yuan per tube, but now it has dropped to 22.6 yuan per tube, a decrease of 92.52%. calculated based on the dosage of 120mg for one course of treatment, the medication cost per patient dropped from 1814.4 yuan to 135.6 yuan.

generally speaking, medical insurance can reimburse about 70% of cancer chemotherapy.for a standard chemotherapy cycle of 6 treatments, the patient’s out-of-pocket cost dropped from 7,620.48 yuan to 569.52 yuan.

before centralized procurement, anti-tumor drugs were expensive and accounted for the majority of disease treatment costs. when doctors talk to family members, they will not only explain the treatment plan, but also often ask about the family's financial situation to weigh and judge medication.some patients can obviously get better treatment results, but their condition worsens because of lack of money. there are countless such examples.

centralized procurement controls drug prices within a reasonable range, reducing the financial burden on patients.doctors can focus all their energy on optimizing diagnosis and treatment plans.this brings good news to the majority of cancer patients. during the interview, chen fang (pseudonym), a nearly 30-year-old breast cancer patient, told the health information bureau that after receiving several courses of centralized drug chemotherapy, she was now able to return to the workplace.

in order to meet different levels of medication needs,if the patient insists on using the original product, the tertiary hospitals will also use it in compliance with the regulations according to the ratio of 30% of non-collected drugs.ensure supply.

the efficacy and safety of centralized procurement of generic drugs are equivalent to those of original drugs

yaorong cloud database shows,there are currently 52 types of anti-tumor drugs entering centralized procurement., covering most of the mainstream clinical drugs, and the market size accounts for more than half of the total drug size. the prices of many centralized anti-tumor drugs have been reduced by more than 90%.

people spend less on medicines, and corresponding hospitals can also make profits. during the visit, the health information bureau found that while implementing the centralized purchasing policy, various public hospitals graduallyoptimize the department assessment system and increase the proportion of medical service revenue in the hospital's total revenue, a long-term mechanism that encourages medical institutions and doctors to rationally use the selected varieties.

during the visit, front-line clinicians told the jianshi bureau that the state food and drug administration has now set up an online reporting platform for adverse drug reactions, and clinicians canif any drug is found to have adverse reactions on patients, it must be reported promptly.and inform all medical practitioners to take note. as of now, no clinical adverse events have been reported for docetaxel or other anti-tumor drugs in centralized drug collections.

the real-world research on the clinical efficacy and safety of generic drugs selected in the second and third batches of national-organized centralized procurement involves 23 representatives in 6 fields including anti-infection, anti-tumor, metabolism and endocrinology, neuropsychiatry, cardiovascular and cerebrovascular, and digestive system acid suppression. sexual variety. the study covered 29 medical institutions in 16 provinces across the country and more than 140,000 clinical cases. the study results show:generic drugs selected through centralized procurement are equivalent to original drugs, which has effectively boosted the trust of all parties in society in the quality of domestic generic drugs.

with the normalization and institutionalization of centralized purchasing, the national medical insurance department, together with the drug regulatory department, has strengthened the quality assurance of the drugs selected through centralized purchasing, so that the people can truly enjoy the "high quality and affordable" centralized purchasing drugs.

written by wang xiaonan

editor丨jiang yunjiating

operation | valley

illustration | visual china

statement: original content from health knowledge bureau. please do not reproduce without permission.

no more hiding, xiaohongshu invites medical supplies companies to discuss business secrets

centralized procurement inadvertently gave birth to a new industry, and local enterprises gave birth to "lucky ones"

new news丨the latest adjustments to the u.s. biosafety act will benefit chinese cxos